PATRICA trial which assessed palbociclib in combination with trastuzumab with or without endocrine therapy in patients with HER2+ advanced BC revealed promising survival outcomes of patients with ER + /HER2 + BC with a PAM50 Luminal A or B subtype treated with trastuzumab [83]. Here, ERBB2 is linked to breast cancer.